Regenerative Medicine
BioStem Technologies to Report First Quarter 2026 Results on May 14
BioStem Technologies will release Q1 2026 financial results on May 14, 2026, followed by a conference call and webcast at 4:30 PM ET, offering investors insight into the company's performance and growth trajectory in regenerative medicine.
Lionheart Health to Showcase Regenerative Technology at Prestigious Medical Innovation Forum
Lionheart Health's upcoming presentation at the Octane Medical Innovation Forum highlights the company's groundbreaking work in organ regeneration and healthspan longevity technologies, signaling significant advancements in the medical aesthetics and aging management industries.
Cellular Therapeutics Market Poised for Rapid Growth, Investors Eye Key Innovators
The global cell therapy market is projected to expand from $7.43 billion to $47.72 billion by 2034, with companies like Adia Nutrition, Fate Therapeutics, Pluri Inc., and Ginkgo Bioworks leading innovative developments in regenerative medicine and cellular technologies.
BioRestorative Therapies Advances Stem Cell Treatments for Chronic Pain and Metabolic Diseases
BioRestorative Therapies is developing innovative stem cell therapies targeting chronic lower back pain, obesity, and type 2 diabetes, potentially offering new treatment options for millions suffering from these conditions.
Creative Biolabs Expands Induced Pluripotent Stem Cell Research Services
Creative Biolabs introduces comprehensive induced pluripotent stem cell (iPSC) services, offering researchers advanced tools to accelerate stem cell therapy research and development across multiple disease domains.